Peripheral Arterial Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older at the time of giving consent
- People receiving first-time treatment using the Cleaner Vac® Thrombectomy System (a device used to remove blood clots in leg or pelvic veins), where at least one part of the device is used inside the body
- People who have given written agreement to take part, using a consent form approved by an ethics review board
- For the blood clot (DVT) group specifically: people who have a blood clot in one or both legs, in at least one of these veins — the femoral-popliteal vein, common femoral vein, iliac vein, or inferior vena cava (the large vein in the abdomen)
- For the DVT group: people whose blood clot has been confirmed by a medical scan within 14 days before the procedure
- For the DVT group: people who have symptoms from the blood clot, and those symptoms started within 6 weeks before joining the trial
Who may not be able to join:
- People who cannot safely take blood-thinning medications at standard treatment doses
- People who are unable to receive iodinated contrast dye (used in certain scans) and for whom pre-medication to reduce a reaction is not possible
- People whose life expectancy is less than one year due to advanced cancer, as assessed by the trial doctor
- People who are pregnant
- People with known blood-clotting disorders — either inherited (such as Factor V Leiden) or acquired (such as Heparin Induced Thrombocytopenia) — that, in the trial doctor's opinion, cannot be safely managed during the study
- People who received clot-dissolving medication (thrombolytics) in the vein being treated within the 14 days before the procedure
- People with known abnormalities in the structure of the inferior vena cava or iliac veins that were present from birth
- People with a known history of a hole between the upper chambers of the heart called a Patent Foramen Ovale (PFO)
- People with certain abnormal blood test results — specifically, haemoglobin below 8.0 g/dL, INR above 2.0 (before starting a blood thinner called warfarin), or platelet count below 50,000/µl — if those values cannot be corrected before joining
- People with severely reduced kidney function (estimated GFR below 30 ml/min) who are not yet on dialysis — note that people with the same level of kidney function who are already on dialysis may still be eligible (confirm with trial site)
- People with a moderate-to-high or high risk pulmonary embolism (a blood clot in the lungs), defined by signs such as dangerously low blood pressure, cardiac arrest, or a combination of heart strain on scans and elevated heart-related blood markers
- People with a complete blockage of the portion of the inferior vena cava below the kidneys
- People who are permanently non-mobile (unable to walk at all)
- People currently enrolled in another clinical trial of an unapproved device or drug that could affect this study's results
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pete Stibbs, Argon Medical Devices
Phone: 469-423-2280
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Technical Success; Composite rate of Major Adverse Events (MAEs) within 30 days post-procedure
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.